The company is developing gene therapy drugs, expanding the indications for use of Neovasculgen and implementing it into medical practice. The company’s research and development focus on angiogenesis, neurotrophic factors, and inflammation.
Neovasculgen is the world’s first registered gene therapy drug for the treatment of lower limb ischemia of atherosclerotic origin. With an innovative mechanism of action, the drug has opened a whole new area in medicine: “therapeutic angiogenesis” (therapeutic generation of blood vessels). Neovasculgen has been used in clinical practice since 2012.
The company is promoting the drug and focuses on expanding its indications for use. Nextgen is conducting clinical trials of Neovasculgen for the treatment of diabetic foot syndrome (DFS) and interstitial cystitis.
Recombinant plasmid DNA-based gene therapy drugs stimulate the formation and growth of collateral vessels. Indications: treatment of conditions that require the development of collateral circulation.
Lower Limb Ischemia
The action of the drug is fundamentally different from all known drugs for the treatment of chronic lower limb ischemia (CLI). This is the world’s first gene therapy drug based on the “therapeutic angiogenesis” mechanism (therapeutic vessel growth).
Neovasculgen stimulates the production of vascular endothelial growth factor VEGF-165, resulting in the growth of new microvasculature at the site of drug administration, which results in better blood supply to the ischemic area.
Clinically, patients show a more than 5-fold increase in pain-free walking distance (PFWD) and an improvement of such indicators as tissue oxygenation, ankle-brachial index, linear blood flow velocity.
The drug is included in the “List of Vital and Essential Drugs” and “National and Clinical Guidelines for CLI Treatment.”
Diabetic Foot Syndrome
Interstitial Cystitis
Androgenetic Alopecia
Peripheral Nerve Injuries